Managing extracranial arteriovenous malformations is challenging. Sirolimus (rapamycin) is increasingly being used when surgery and embolization are not advised. Because of its anti-angiogenic properties here we report all extracranial arteriovenous malformation cases treated with sirolimus in 2 French tertiary centers for vascular anomalies. The outcomes were efficacy (complete, partial, no response) based on arteriovenous malformation volume and necrosis/hemorrhage and side effects. We retrospectively included 10 patients (7 children). The sirolimus dose ranged from 0.6 to 3.5 mg/m2. Median (interquartile range [IQR]) treatment time was 24.5 (4.5; 35) months. Five patients showed no response and 5 showed partial response at a median (IQR) of 3 (1; 5) months followed in 2 cases by therapeutic resistance (i.e., progressive disease after 9 and 24 months of treatment). The most frequent side effect was mouth ulcers. This study shows poor efficacy of sirolimus for treating extracranial arteriovenous malformations.

Download full-text PDF

Source
http://dx.doi.org/10.2340/00015555-3273DOI Listing

Publication Analysis

Top Keywords

extracranial arteriovenous
16
arteriovenous malformations
12
sirolimus rapamycin
8
arteriovenous malformation
8
partial response
8
sirolimus
5
arteriovenous
5
efficacy tolerance
4
tolerance sirolimus
4
extracranial
4

Similar Publications

Background: Arteriovenous malformations (AVMs) account for <3% of vascular anomalies. This study aims to present the 10-year experience of a German vascular anomaly center (VAC) with AVMs and evaluate diagnostic imaging for treatment-relevant information for minimally invasive therapy planning.

Material And Methods: A retrospective study including patients from the VAC database with AVMs was conducted.

View Article and Find Full Text PDF

Vertebro-vertebral arteriovenous fistula (VV-AVF) is an uncommon vascular disorder characterized by an abnormal direct connection between the extracranial vertebral artery (VA), as well as the first and second branches of subclavian arteries, and the draining veins of the paravertebral venous plexus. Endovascular occlusion or surgical ligation of the high-flow arteriovenous fistula is the main goal of treatment for VV-AVF, but there are no guidelines for the best treatment to date. Endovascular treatment is the primary treatment procedure due to its safety, effectiveness, and simplicity.

View Article and Find Full Text PDF

Background: Venous hypertensive myelopathy (VHM), formerly known as "Foix-Alajouanine syndrome," is a spinal cord dysfunction caused by impaired perfusion of the spinal cord. Most cases are attributed to spinal dural arteriovenous fistulas (dAVFs), but there are scattered reports of VHM without concomitant dAVF. Furthermore, no cases of VHM associated with intracranial hemorrhage exist.

View Article and Find Full Text PDF

We present a case of a rare vascular variation of the persistent hypoglossal artery (PHA) in a 57-year-old Caucasian female patient with a medical history of poorly controlled hypertension, headaches, diabetes mellitus, and depression. This anatomical variation was initially misdiagnosed as an internal carotid artery (ICA) aneurysm during the extracranial carotid Doppler imaging conducted due to nonspecific symptoms of cerebrovascular insufficiency, manifesting as coordination disturbances. PHA is one of the four vertebrobasilar anastomoses, originating from the cervical segment of the ICA.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!